Cargando…

Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy

Current cell-free DNA (cfDNA) next generation sequencing (NGS) precision oncology workflows are typically limited to targeted and/or disease-specific applications. In advanced cancer, disease burden and cfDNA tumor content are often elevated, yielding unique precision oncology opportunities. We soug...

Descripción completa

Detalles Bibliográficos
Autores principales: Hovelson, Daniel H., Liu, Chia-Jen, Wang, Yugang, Kang, Qing, Henderson, James, Gursky, Amy, Brockman, Scott, Ramnath, Nithya, Krauss, John C., Talpaz, Moshe, Kandarpa, Malathi, Chugh, Rashmi, Tuck, Missy, Herman, Kirk, Grasso, Catherine S., Quist, Michael J., Feng, Felix Y., Haakenson, Christine, Langmore, John, Kamberov, Emmanuel, Tesmer, Tim, Husain, Hatim, Lonigro, Robert J., Robinson, Dan, Smith, David C., Alva, Ajjai S., Hussain, Maha H., Chinnaiyan, Arul M., Tewari, Muneesh, Mills, Ryan E., Morgan, Todd M., Tomlins, Scott A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685714/
https://www.ncbi.nlm.nih.gov/pubmed/29163793
http://dx.doi.org/10.18632/oncotarget.21163
_version_ 1783278671476293632
author Hovelson, Daniel H.
Liu, Chia-Jen
Wang, Yugang
Kang, Qing
Henderson, James
Gursky, Amy
Brockman, Scott
Ramnath, Nithya
Krauss, John C.
Talpaz, Moshe
Kandarpa, Malathi
Chugh, Rashmi
Tuck, Missy
Herman, Kirk
Grasso, Catherine S.
Quist, Michael J.
Feng, Felix Y.
Haakenson, Christine
Langmore, John
Kamberov, Emmanuel
Tesmer, Tim
Husain, Hatim
Lonigro, Robert J.
Robinson, Dan
Smith, David C.
Alva, Ajjai S.
Hussain, Maha H.
Chinnaiyan, Arul M.
Tewari, Muneesh
Mills, Ryan E.
Morgan, Todd M.
Tomlins, Scott A.
author_facet Hovelson, Daniel H.
Liu, Chia-Jen
Wang, Yugang
Kang, Qing
Henderson, James
Gursky, Amy
Brockman, Scott
Ramnath, Nithya
Krauss, John C.
Talpaz, Moshe
Kandarpa, Malathi
Chugh, Rashmi
Tuck, Missy
Herman, Kirk
Grasso, Catherine S.
Quist, Michael J.
Feng, Felix Y.
Haakenson, Christine
Langmore, John
Kamberov, Emmanuel
Tesmer, Tim
Husain, Hatim
Lonigro, Robert J.
Robinson, Dan
Smith, David C.
Alva, Ajjai S.
Hussain, Maha H.
Chinnaiyan, Arul M.
Tewari, Muneesh
Mills, Ryan E.
Morgan, Todd M.
Tomlins, Scott A.
author_sort Hovelson, Daniel H.
collection PubMed
description Current cell-free DNA (cfDNA) next generation sequencing (NGS) precision oncology workflows are typically limited to targeted and/or disease-specific applications. In advanced cancer, disease burden and cfDNA tumor content are often elevated, yielding unique precision oncology opportunities. We sought to demonstrate the utility of a pan-cancer, rapid, inexpensive, whole genome NGS of cfDNA approach (PRINCe) as a precision oncology screening strategy via ultra-low coverage (~0.01x) tumor content determination through genome-wide copy number alteration (CNA) profiling. We applied PRINCe to a retrospective cohort of 124 cfDNA samples from 100 patients with advanced cancers, including 76 men with metastatic castration-resistant prostate cancer (mCRPC), enabling cfDNA tumor content approximation and actionable focal CNA detection, while facilitating concordance analyses between cfDNA and tissue-based NGS profiles and assessment of cfDNA alteration associations with mCRPC treatment outcomes. Therapeutically relevant focal CNAs were present in 42 (34%) cfDNA samples, including 36 of 93 (39%) mCRPC patient samples harboring AR amplification. PRINCe identified pre-treatment cfDNA CNA profiles facilitating disease monitoring. Combining PRINCe with routine targeted NGS of cfDNA enabled mutation and CNA assessment with coverages tuned to cfDNA tumor content. In mCRPC, genome-wide PRINCe cfDNA and matched tissue CNA profiles showed high concordance (median Pearson correlation = 0.87), and PRINCe detectable AR amplifications predicted reduced time on therapy, independent of therapy type (Kaplan-Meier log-rank test, chi-square = 24.9, p < 0.0001). Our screening approach enables robust, broadly applicable cfDNA-based precision oncology for patients with advanced cancer through scalable identification of therapeutically relevant CNAs and pre-/post-treatment genomic profiles, enabling cfDNA- or tissue-based precision oncology workflow optimization.
format Online
Article
Text
id pubmed-5685714
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-56857142017-11-21 Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy Hovelson, Daniel H. Liu, Chia-Jen Wang, Yugang Kang, Qing Henderson, James Gursky, Amy Brockman, Scott Ramnath, Nithya Krauss, John C. Talpaz, Moshe Kandarpa, Malathi Chugh, Rashmi Tuck, Missy Herman, Kirk Grasso, Catherine S. Quist, Michael J. Feng, Felix Y. Haakenson, Christine Langmore, John Kamberov, Emmanuel Tesmer, Tim Husain, Hatim Lonigro, Robert J. Robinson, Dan Smith, David C. Alva, Ajjai S. Hussain, Maha H. Chinnaiyan, Arul M. Tewari, Muneesh Mills, Ryan E. Morgan, Todd M. Tomlins, Scott A. Oncotarget Research Paper Current cell-free DNA (cfDNA) next generation sequencing (NGS) precision oncology workflows are typically limited to targeted and/or disease-specific applications. In advanced cancer, disease burden and cfDNA tumor content are often elevated, yielding unique precision oncology opportunities. We sought to demonstrate the utility of a pan-cancer, rapid, inexpensive, whole genome NGS of cfDNA approach (PRINCe) as a precision oncology screening strategy via ultra-low coverage (~0.01x) tumor content determination through genome-wide copy number alteration (CNA) profiling. We applied PRINCe to a retrospective cohort of 124 cfDNA samples from 100 patients with advanced cancers, including 76 men with metastatic castration-resistant prostate cancer (mCRPC), enabling cfDNA tumor content approximation and actionable focal CNA detection, while facilitating concordance analyses between cfDNA and tissue-based NGS profiles and assessment of cfDNA alteration associations with mCRPC treatment outcomes. Therapeutically relevant focal CNAs were present in 42 (34%) cfDNA samples, including 36 of 93 (39%) mCRPC patient samples harboring AR amplification. PRINCe identified pre-treatment cfDNA CNA profiles facilitating disease monitoring. Combining PRINCe with routine targeted NGS of cfDNA enabled mutation and CNA assessment with coverages tuned to cfDNA tumor content. In mCRPC, genome-wide PRINCe cfDNA and matched tissue CNA profiles showed high concordance (median Pearson correlation = 0.87), and PRINCe detectable AR amplifications predicted reduced time on therapy, independent of therapy type (Kaplan-Meier log-rank test, chi-square = 24.9, p < 0.0001). Our screening approach enables robust, broadly applicable cfDNA-based precision oncology for patients with advanced cancer through scalable identification of therapeutically relevant CNAs and pre-/post-treatment genomic profiles, enabling cfDNA- or tissue-based precision oncology workflow optimization. Impact Journals LLC 2017-09-22 /pmc/articles/PMC5685714/ /pubmed/29163793 http://dx.doi.org/10.18632/oncotarget.21163 Text en Copyright: © 2017 Hovelson et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (http://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Hovelson, Daniel H.
Liu, Chia-Jen
Wang, Yugang
Kang, Qing
Henderson, James
Gursky, Amy
Brockman, Scott
Ramnath, Nithya
Krauss, John C.
Talpaz, Moshe
Kandarpa, Malathi
Chugh, Rashmi
Tuck, Missy
Herman, Kirk
Grasso, Catherine S.
Quist, Michael J.
Feng, Felix Y.
Haakenson, Christine
Langmore, John
Kamberov, Emmanuel
Tesmer, Tim
Husain, Hatim
Lonigro, Robert J.
Robinson, Dan
Smith, David C.
Alva, Ajjai S.
Hussain, Maha H.
Chinnaiyan, Arul M.
Tewari, Muneesh
Mills, Ryan E.
Morgan, Todd M.
Tomlins, Scott A.
Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy
title Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy
title_full Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy
title_fullStr Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy
title_full_unstemmed Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy
title_short Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy
title_sort rapid, ultra low coverage copy number profiling of cell-free dna as a precision oncology screening strategy
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685714/
https://www.ncbi.nlm.nih.gov/pubmed/29163793
http://dx.doi.org/10.18632/oncotarget.21163
work_keys_str_mv AT hovelsondanielh rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy
AT liuchiajen rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy
AT wangyugang rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy
AT kangqing rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy
AT hendersonjames rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy
AT gurskyamy rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy
AT brockmanscott rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy
AT ramnathnithya rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy
AT kraussjohnc rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy
AT talpazmoshe rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy
AT kandarpamalathi rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy
AT chughrashmi rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy
AT tuckmissy rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy
AT hermankirk rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy
AT grassocatherines rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy
AT quistmichaelj rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy
AT fengfelixy rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy
AT haakensonchristine rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy
AT langmorejohn rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy
AT kamberovemmanuel rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy
AT tesmertim rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy
AT husainhatim rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy
AT lonigrorobertj rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy
AT robinsondan rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy
AT smithdavidc rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy
AT alvaajjais rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy
AT hussainmahah rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy
AT chinnaiyanarulm rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy
AT tewarimuneesh rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy
AT millsryane rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy
AT morgantoddm rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy
AT tomlinsscotta rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy